FDA Expected to Approve First Vaccines Targeting Respiratory Infections

Pfizer's RSV vaccine shows 82% effectiveness in preventing severe infections in infants.
FDA decision on RSV vaccines expected in fall 2022; several companies developing vaccines for older adults.
Nasal spray COVID-19 vaccine shows strong immune response in study; trials underway for 12 nasal spray vaccines.
WHO urges China to share information as COVID-19 origins remain unknown; raccoon dogs may have played a role in transmission.
RSV cases in the U.S. starting to show normal seasonal patterns again as companies await approval of vaccines for high-risk groups.